SGI-1776 is a small-molecule pan-Pim protein kinase inhibitor with potential antineoplastic activity. Pim kinase inhibitor SGI-1776 binds to and inhibits the activities of Pim-1, -2 and -3, serine-threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of pro-apoptotic Bcl2 proteins and tumor cell apoptosis. PIM kinases play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.
FLT3 Inhibitors Related Products:
Crenolanib; Dovitinib; FLX925; Quizartinib; Brigatinib; Pacritinib; Fedratinib; TG101209; Tandutinib; SU5614; Tamatinib; G-749